Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders

Abstract

The present invention relates to methods, compositions, and kits for detecting and quantitating biomarkers on vesicles without lysis or permeabilization of the vesicles and the use of biomarkers identified on vesicles in diagnostic and prognostic methods for various diseases and disorders. Disease and disorders of the present invention include neurological disorders, immunological disorders, placental diseases, and cancer.

What is claimed is: 
     
         1 . A method comprising:
 a) providing a biological sample comprising vesicles;   b) contacting a solid support comprising capture agents associated therewith with the biological sample under conditions wherein the capture agents selectively bind to a first biomarker, if present, on the vesicles, thereby capturing said vesicles having said first biomarker on the solid support;   c) separating the solid support from the biological sample; and   d) detecting a second biomarker on the vesicles captured on the solid support using a detection agent that selectively binds to the second biomarker, wherein the vesicles are not lysed or permeabilized.   
     
     
         2 . The method of  claim 1 , wherein the first and second biomarkers are membrane-bound proteins or adsorbed proteins on the vesicles. 
     
     
         3 . The method of  claim 1 , wherein the first or second biomarker is an exosome surface marker. 
     
     
         4 . The method of  claim 3 , wherein the exosome surface marker is CD81, CD63, CD171, SNAP25, EAAT1, DAT, CD11b or OMG. 
     
     
         5 . The method of  claim 1 , wherein the first or second biomarker is selected from the group consisting of a neuron-specific protein, an astrocyte-specific protein, a microglia-specific protein, and an oligodendrocyte-specific protein. 
     
     
         6 . The method of  claim 5 , wherein the neuron-specific protein is selected from the group consisting of NRGN, Tau, phosphorylated Tau, synaptophysin, αβ-42, alpha-synuclein (SNCA), AchE, LAMP1, REST, SYT, SYP, SYNPO, PSD95, SV2A, CCL2, IL34, GYS, OR, DR6, HSP, IL12b, Aβ, and BACE. 
     
     
         7 . The method of  claim 5 , wherein the astrocyte-specific proteins is selected from the group consisting of glial fibrillary acidic protein (GFAP) and excitatory amino acid transporter 1 (EAAT1). 
     
     
         8 . The method of  claim 5 , wherein the oligodendrocyte-specific protein is selected from the group consisting of myelin basic protein (MBP) and oligodendrocyte myelin glycoprotein (OMG). 
     
     
         9 . The method of  claim 5 , wherein the vesicles captured on the solid support are selected from the group consisting of neuron-derived exosomes, astrocyte-derived exosomes, oligodendrocyte-derived exosomes, and microglia-derived exosomes. 
     
     
         10 . The method of  claim 2 , wherein the membrane-bound proteins or adsorbed proteins on the vesicles is dopamine transporter (DAT) or tyrosine hydroxygenase (TH). 
     
     
         11 . The method of  claim 1 , further comprising detecting a cytosolic protein on the vesicles captured on the solid support. 
     
     
         12 . The method of  claim 11 , wherein the cytosolic protein is GAPDH, CTSD, NRGN, MBP, GFAP, Tau, phosphorylated Tau (e.g., T181), synaptophysin, SNCA, αβ-42, AchE, LAMP1, REST, SYT, TH, SYP, SYNPO, PSD95, SV2A, GYS, HSP70, BACE, SYMPO, NEFL, caspase, ubiquitin, PSEN1, GSK, PLAP, CSH1, or PSG1. 
     
     
         13 . The method of  claim 12 , wherein the cytosolic protein is a pathological form, including aggregates and/or mutated form of GAPDH, CTSD, NRGN, MBP, GFAP, Tau, phosphorylated Tau (e.g., T181), synaptophysin, SNCA, αβ-42, AchE, LAMP1, REST, SYT, TH, SYP, SYNPO, PSD95, SV2A, GYS, HSP70, BACE, SYMPO, NEFL, caspase, ubiquitin, PSEN1, GSK, PLAP, CSH1, or PSG1. 
     
     
         14 . The method of  claim 1 , further comprising detecting a secretory protein on the vesicles captured on the solid support. 
     
     
         15 . The method of  claim 14 , wherein the secretory protein is selected from the group consisting of cytokines, growth factors, chemokines, interleukins, nociceptin (opioid peptide), and GnRH. 
     
     
         16 . The method of  claim 15 , wherein the cytokine is selected from the group consisting of IL1b, IL34, IL6, IL8, IL16, IL23A, IL32, IL33, CX3CL1, CCL2, CXCL12, TNFalpha, TNFSF10, TNFSF13, IL12B, and FasL. 
     
     
         17 . The method of  claim 1 , further comprising detecting a receptor protein, a transporter protein, or a membrane protein on the vesicles captured on the solid support. 
     
     
         18 . The method of  claim 17 , wherein the receptor protein is a neurotransmitter receptor, a dopamine receptor, a serotonin receptor, a GABA receptor, a glutamate receptor, an insulin receptor, a tumor necrosis factor receptor, or a neuropeptide receptor. 
     
     
         19 . The method of  claim 17 , wherein the membrane protein is EpCAM, PD-L1, ErbB2, CK19, TCR, CD16, CD28, CD32, CD79a, TREM2, or NCAM. 
     
     
         20 . The method of  claim 17 , wherein the transporter protein is a neurotransmitter transporter, a dopamine transporter (DAT), a serotonin transporter, a GABA transporter, a glutamate transporter, an insulin transporter, a tumor necrosis factor transporter, or a neuropeptide transporter. 
     
     
         21 . The method of  claim 1 , wherein the solid support is a plate, a non-magnetic bead, a magnetic bead, a filter, a slide, a wafer, a rod, a particle, a strand, a disc, a membrane, or a surface of a tube, channel, column, flow cell device, or microfluidic device. 
     
     
         22 . The method of  claim 1 , wherein the capture agents comprise antibodies, antibody fragments, antibody mimetics, or aptamers that specifically bind to the first biomarker on the vesicles. 
     
     
         23 . The method of  claim 1 , wherein the detection agent comprises an antibody, an antibody fragment, an antibody mimetic, or an aptamer that specifically binds to the second biomarker on the vesicles. 
     
     
         24 . The method of  claim 1 , wherein said detecting comprises performing an immunoassay. 
     
     
         25 . The method of  claim 24 , wherein the immunoassay is selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA), an immunofluorescent assay (IFA), an immune-polymerase chain reaction assay, an electro-chemiluminescence immunoassay (ECLIA), and a radioimmunoassay (RIA).